Symbols / SPRO Stock $2.63 +1.54% Spero Therapeutics, Inc.
SPRO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Ratings
Current target
$2.63
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-20 | down | Evercore ISI Group | Outperform → In-Line | $5 |
| 2024-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-18 | down | TD Cowen | Buy → Hold | — |
| 2024-11-15 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-04 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-06 | up | TD Cowen | Hold → Buy | — |
| 2024-08-06 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-04-04 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-09-05 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-08-14 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-07-20 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-04-10 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2022-09-26 | main | HC Wainwright & Co. | — → Buy | $6 |
- Spero Therapeutics, Inc. Common Stock SPRO ) Stock Price Today & Analysis - Gotrade Sun, 17 May 2026 08
- FDA to rule June 18 on Spero oral antibiotic for severe UTIs - Stock Titan Wed, 13 May 2026 20
- Insider Sale: Chief Operating Officer of $SPRO Sells 18,891 Shares | SPRO Stock News - Quiver Quantitative hu, 05 Feb 2026 08
- Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha Wed, 11 Feb 2026 08
- Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance Mon, 15 Dec 2025 08
- Spero Therapeutics (SPRO) to Release Quarterly Earnings on Wednesday - MarketBeat Wed, 06 May 2026 07
- Promising Penny Stocks To Consider In May 2026 - simplywall.st Fri, 15 May 2026 11
- Number of shareholders of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView Sat, 09 May 2026 15
- No call planned as Spero sets May 13 for Q1 results update - Stock Titan ue, 05 May 2026 07
- Spero Therapeutics CEO sells $63,352 in company stock - Investing.com Wed, 06 May 2026 07
- Insider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 25,240 Shares of Stock - MarketBeat Wed, 06 May 2026 07
- Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock - simplywall.st Sat, 14 Feb 2026 08
- Spero’s oral UTI antibiotic faces FDA decision on June 18 - Stock Titan hu, 26 Mar 2026 07
- Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest - MarketBeat hu, 30 Apr 2026 07
- Spero Therapeutics to post Q4 and 2025 results on March 26 - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
59.62
+117.62%
|
27.40
-71.68%
|
96.73
+99.13%
|
48.58
|
| Operating Revenue |
|
59.62
+117.62%
|
27.40
-71.68%
|
96.73
+99.13%
|
48.58
|
| Operating Expense |
|
52.46
-47.48%
|
99.88
+42.79%
|
69.95
-11.62%
|
79.15
|
| Research And Development |
|
38.47
-60.24%
|
96.76
+88.10%
|
51.44
+8.08%
|
47.59
|
| Selling General And Administration |
|
21.18
-10.66%
|
23.70
-7.24%
|
25.55
-29.96%
|
36.48
|
| General And Administrative Expense |
|
21.18
-10.66%
|
23.70
-7.24%
|
25.55
-29.96%
|
36.48
|
| Salaries And Wages |
|
11.79
-10.59%
|
13.19
-13.94%
|
15.32
-25.00%
|
20.43
|
| Other Gand A |
|
9.38
-10.76%
|
10.52
+2.80%
|
10.23
-36.26%
|
16.05
|
| Other Operating Expenses |
|
-7.18
+65.10%
|
-20.58
-192.09%
|
-7.05
-42.92%
|
-4.93
|
| Total Expenses |
|
52.46
-47.48%
|
99.88
+42.79%
|
69.95
-11.62%
|
79.15
|
| Operating Income |
|
7.16
+109.88%
|
-72.48
-370.59%
|
26.79
+187.63%
|
-30.57
|
| Total Operating Income As Reported |
|
6.31
+108.61%
|
-73.36
-441.52%
|
21.48
+150.91%
|
-42.20
|
| EBITDA |
|
7.16
+109.88%
|
-72.48
-366.93%
|
27.15
+163.24%
|
-42.94
|
| Normalized EBITDA |
|
8.00
+111.18%
|
-71.61
-320.59%
|
32.46
+200.72%
|
-32.23
|
| Reconciled Depreciation |
|
0.00
-100.00%
|
0.00
-99.46%
|
0.37
-57.77%
|
0.87
|
| EBIT |
|
7.16
+109.88%
|
-72.48
-370.59%
|
26.79
+161.14%
|
-43.81
|
| Total Unusual Items |
|
-0.84
+3.65%
|
-0.88
+83.47%
|
-5.31
+50.47%
|
-10.71
|
| Total Unusual Items Excluding Goodwill |
|
-0.84
+3.65%
|
-0.88
+83.47%
|
-5.31
+50.47%
|
-10.71
|
| Special Income Charges |
|
-0.84
+3.65%
|
-0.88
+83.47%
|
-5.31
+54.38%
|
-11.63
|
| Other Special Charges |
|
—
|
—
|
—
|
3.58
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
5.31
|
0.00
|
| Restructuring And Mergern Acquisition |
|
0.26
-70.58%
|
0.88
|
0.00
-100.00%
|
11.63
|
| Write Off |
|
0.59
|
0.00
-100.00%
|
5.31
|
0.00
|
| Net Income |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Pretax Income |
|
8.83
+112.88%
|
-68.57
-369.90%
|
25.40
+154.73%
|
-46.41
|
| Net Non Operating Interest Income Expense |
|
2.51
-46.95%
|
4.74
+20.27%
|
3.94
+362.64%
|
-1.50
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
2.60
|
| Net Interest Income |
|
2.51
-46.95%
|
4.74
+20.27%
|
3.94
+362.64%
|
-1.50
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
2.60
|
| Interest Income Non Operating |
|
2.51
-46.95%
|
4.74
+20.27%
|
3.94
+255.97%
|
1.11
|
| Interest Income |
|
2.51
-46.95%
|
4.74
+20.27%
|
3.94
+255.97%
|
1.11
|
| Other Income Expense |
|
-0.84
-2.57%
|
-0.82
+84.64%
|
-5.32
+62.92%
|
-14.35
|
| Other Non Operating Income Expenses |
|
0.01
-88.33%
|
0.06
+528.57%
|
-0.01
+99.61%
|
-3.64
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
0.92
|
| Tax Provision |
|
0.26
|
0.00
-100.00%
|
2.60
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.03
|
0.00
+100.00%
|
-0.54
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Net Income From Continuing Operation Net Minority Interest |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Net Income From Continuing And Discontinued Operation |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Net Income Continuous Operations |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Normalized Income |
|
9.39
+113.87%
|
-67.69
-345.51%
|
27.57
+177.22%
|
-35.70
|
| Net Income Common Stockholders |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Diluted EPS |
|
0.15
+111.81%
|
-1.27
-395.35%
|
0.43
+134.96%
|
-1.23
|
| Basic EPS |
|
0.15
+111.81%
|
-1.27
-395.35%
|
0.43
+134.96%
|
-1.23
|
| Basic Average Shares |
|
56.02
+3.67%
|
54.04
+2.53%
|
52.70
+40.22%
|
37.59
|
| Diluted Average Shares |
|
59.04
+9.26%
|
54.04
+1.98%
|
52.99
+40.98%
|
37.59
|
| Diluted NI Availto Com Stockholders |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
68.92
-37.65%
|
110.54
-39.39%
|
182.39
+46.14%
|
124.80
|
| Current Assets |
|
67.29
-37.28%
|
107.28
-18.24%
|
131.21
+15.53%
|
113.57
|
| Cash Cash Equivalents And Short Term Investments |
|
40.27
-23.87%
|
52.89
-30.71%
|
76.33
-30.04%
|
109.11
|
| Cash And Cash Equivalents |
|
40.27
-23.87%
|
52.89
-30.71%
|
76.33
-30.04%
|
109.11
|
| Cash Equivalents |
|
39.67
-24.08%
|
52.26
|
—
|
—
|
| Cash Financial |
|
0.59
-6.02%
|
0.63
|
—
|
—
|
| Other Short Term Investments |
|
—
|
—
|
—
|
0.00
|
| Receivables |
|
25.39
-51.62%
|
52.48
+3.51%
|
50.70
+4576.85%
|
1.08
|
| Other Receivables |
|
0.03
-99.09%
|
3.08
+99.68%
|
1.54
+42.53%
|
1.08
|
| Taxes Receivable |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
1.63
-14.50%
|
1.91
-54.26%
|
4.18
+23.65%
|
3.38
|
| Total Non Current Assets |
|
1.63
-50.02%
|
3.27
-93.62%
|
51.18
+355.68%
|
11.23
|
| Net PPE |
|
1.48
-52.47%
|
3.11
-25.09%
|
4.16
-24.31%
|
5.49
|
| Gross PPE |
|
1.48
-52.47%
|
3.11
-59.95%
|
7.78
-11.08%
|
8.74
|
| Accumulated Depreciation |
|
—
|
-3.62
-0.06%
|
-3.62
-11.25%
|
-3.25
|
| Properties |
|
—
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
0.65
+0.00%
|
0.65
+0.00%
|
0.65
|
| Construction In Progress |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
1.48
-52.47%
|
3.11
-43.31%
|
5.49
-15.00%
|
6.46
|
| Leases |
|
—
|
1.64
+0.00%
|
1.64
+0.00%
|
1.64
|
| Non Current Accounts Receivable |
|
—
|
—
|
46.59
|
—
|
| Other Non Current Assets |
|
0.15
+0.00%
|
0.15
-64.83%
|
0.43
-92.42%
|
5.74
|
| Total Liabilities Net Minority Interest |
|
9.90
-84.64%
|
64.42
-14.67%
|
75.50
+54.49%
|
48.87
|
| Current Liabilities |
|
8.87
-81.93%
|
49.07
+32.09%
|
37.15
+71.62%
|
21.65
|
| Payables And Accrued Expenses |
|
6.65
-73.60%
|
25.20
+202.86%
|
8.32
-13.22%
|
9.59
|
| Payables |
|
1.08
-85.61%
|
7.48
+323.80%
|
1.76
+186.06%
|
0.62
|
| Accounts Payable |
|
0.69
-90.51%
|
7.31
+430.19%
|
1.38
+123.34%
|
0.62
|
| Current Accrued Expenses |
|
5.58
-68.53%
|
17.72
+170.31%
|
6.56
-26.93%
|
8.97
|
| Total Tax Payable |
|
0.38
+120.11%
|
0.17
-55.04%
|
0.39
|
0.00
|
| Income Tax Payable |
|
0.38
+120.11%
|
0.17
-55.04%
|
0.39
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
1.96
+12.03%
|
1.75
+1.63%
|
1.72
+1.66%
|
1.69
|
| Current Capital Lease Obligation |
|
1.96
+12.03%
|
1.75
+1.63%
|
1.72
+1.66%
|
1.69
|
| Current Deferred Liabilities |
|
0.26
-98.83%
|
22.12
-18.40%
|
27.11
+161.48%
|
10.37
|
| Current Deferred Revenue |
|
0.26
-98.83%
|
22.12
-18.40%
|
27.11
+161.48%
|
10.37
|
| Total Non Current Liabilities Net Minority Interest |
|
1.03
-93.29%
|
15.35
-59.98%
|
38.34
+40.87%
|
27.22
|
| Long Term Debt And Capital Lease Obligation |
|
0.94
-63.19%
|
2.55
-33.31%
|
3.83
-22.84%
|
4.96
|
| Long Term Capital Lease Obligation |
|
0.94
-63.19%
|
2.55
-33.31%
|
3.83
-22.84%
|
4.96
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
12.22
+12.88%
|
10.82
+11.13%
|
9.74
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
12.22
+12.88%
|
10.82
+11.13%
|
9.74
|
| Other Non Current Liabilities |
|
0.09
|
—
|
0.09
-9.38%
|
0.10
|
| Stockholders Equity |
|
59.02
+27.96%
|
46.12
-56.85%
|
106.89
+40.77%
|
75.93
|
| Common Stock Equity |
|
59.02
+27.96%
|
46.12
-56.85%
|
106.89
+40.77%
|
75.93
|
| Capital Stock |
|
0.06
+1.82%
|
0.06
+3.77%
|
0.05
+1.92%
|
0.05
|
| Common Stock |
|
0.06
+1.82%
|
0.06
+3.77%
|
0.05
+1.92%
|
0.05
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
56.41
+3.34%
|
54.59
+3.01%
|
53.00
+1.04%
|
52.46
|
| Ordinary Shares Number |
|
56.41
+3.34%
|
54.59
+3.01%
|
53.00
+1.04%
|
52.46
|
| Additional Paid In Capital |
|
510.03
+0.86%
|
505.71
+1.57%
|
497.91
+1.66%
|
489.76
|
| Retained Earnings |
|
-451.07
+1.86%
|
-459.64
-17.53%
|
-391.07
+5.51%
|
-413.88
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
0.00
|
0.00
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
59.02
+27.96%
|
46.12
-56.85%
|
106.89
+40.77%
|
75.93
|
| Total Capitalization |
|
59.02
+27.96%
|
46.12
-56.85%
|
106.89
+40.77%
|
75.93
|
| Working Capital |
|
58.42
+0.37%
|
58.20
-38.12%
|
94.06
+2.32%
|
91.92
|
| Invested Capital |
|
59.02
+27.96%
|
46.12
-56.85%
|
106.89
+40.77%
|
75.93
|
| Total Debt |
|
2.90
-32.63%
|
4.30
-22.48%
|
5.54
-16.61%
|
6.65
|
| Capital Lease Obligations |
|
2.90
-32.63%
|
4.30
-22.48%
|
5.54
-16.61%
|
6.65
|
| Net Tangible Assets |
|
59.02
+27.96%
|
46.12
-56.85%
|
106.89
+40.77%
|
75.93
|
| Tangible Book Value |
|
59.02
+27.96%
|
46.12
-56.85%
|
106.89
+40.77%
|
75.93
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
0.58
-97.56%
|
23.61
+89.99%
|
12.43
|
| Duefrom Related Parties Current |
|
25.36
-48.66%
|
49.39
+0.49%
|
49.15
|
0.00
|
| Duefrom Related Parties Non Current |
|
—
|
0.00
-100.00%
|
46.59
|
—
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-12.62
+46.15%
|
-23.44
+28.95%
|
-32.99
-326.79%
|
-7.73
|
| Cash Flow From Continuing Operating Activities |
|
-12.62
+46.15%
|
-23.44
+28.95%
|
-32.99
-326.79%
|
-7.73
|
| Net Income From Continuing Operations |
|
8.57
+112.50%
|
-68.57
-400.65%
|
22.81
+149.13%
|
-46.41
|
| Depreciation Amortization Depletion |
|
0.00
-100.00%
|
0.00
-99.46%
|
0.37
-57.77%
|
0.87
|
| Depreciation And Amortization |
|
0.00
-100.00%
|
0.00
-99.46%
|
0.37
-57.77%
|
0.87
|
| Other Non Cash Items |
|
1.05
+0.48%
|
1.04
+7.64%
|
0.97
-70.48%
|
3.28
|
| Stock Based Compensation |
|
4.33
-44.50%
|
7.79
-1.75%
|
7.93
-13.05%
|
9.12
|
| Asset Impairment Charge |
|
0.59
|
0.00
-100.00%
|
5.31
+735.59%
|
0.64
|
| Operating Gains Losses |
|
—
|
—
|
—
|
2.67
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.92
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Change In Working Capital |
|
-27.16
-174.84%
|
36.28
+151.56%
|
-70.38
-418.63%
|
22.09
|
| Change In Receivables |
|
3.06
+298.51%
|
-1.54
-234.06%
|
-0.46
-129.80%
|
1.55
|
| Change In Prepaid Assets |
|
0.28
-87.78%
|
2.27
+383.73%
|
-0.80
-115.24%
|
5.24
|
| Change In Payables And Accrued Expense |
|
-18.55
-209.88%
|
16.88
+1431.39%
|
-1.27
+78.37%
|
-5.86
|
| Change In Accrued Expense |
|
-12.15
-208.77%
|
11.17
+562.21%
|
-2.42
+55.07%
|
-5.38
|
| Change In Payable |
|
-6.40
-212.06%
|
5.71
+397.82%
|
1.15
+337.19%
|
-0.48
|
| Change In Account Payable |
|
-6.61
-211.56%
|
5.93
+678.98%
|
0.76
+257.23%
|
-0.48
|
| Change In Other Working Capital |
|
-34.66
-30.18%
|
-26.62
-191.78%
|
29.01
+32.51%
|
21.89
|
| Change In Other Current Assets |
|
24.03
-48.47%
|
46.63
+148.71%
|
-95.74
-3191333.33%
|
-0.00
|
| Change In Other Current Liabilities |
|
-1.31
+1.65%
|
-1.33
-19.77%
|
-1.11
-52.47%
|
-0.73
|
| Investing Cash Flow |
|
—
|
—
|
0.00
-100.00%
|
33.81
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
0.00
-100.00%
|
33.81
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Net Investment Purchase And Sale |
|
—
|
—
|
0.00
-100.00%
|
33.81
|
| Purchase Of Investment |
|
—
|
—
|
0.00
+100.00%
|
-26.97
|
| Sale Of Investment |
|
—
|
—
|
0.00
-100.00%
|
60.78
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
—
|
0.00
-100.00%
|
0.22
+100.75%
|
-29.55
|
| Cash Flow From Continuing Financing Activities |
|
—
|
0.00
-100.00%
|
0.22
+100.75%
|
-29.55
|
| Net Common Stock Issuance |
|
—
|
0.00
-100.00%
|
0.22
-99.10%
|
24.51
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
-100.00%
|
0.42
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-54.48
|
| Changes In Cash |
|
-12.62
+46.15%
|
-23.44
+28.47%
|
-32.77
-842.59%
|
-3.48
|
| Beginning Cash Position |
|
52.89
-30.71%
|
76.33
-30.04%
|
109.11
-3.09%
|
112.58
|
| End Cash Position |
|
40.27
-23.87%
|
52.89
-30.71%
|
76.33
-30.04%
|
109.11
|
| Free Cash Flow |
|
-12.62
+46.15%
|
-23.44
+28.95%
|
-32.99
-326.79%
|
-7.73
|
| Income Tax Paid Supplemental Data |
|
—
|
0.10
-95.52%
|
2.21
|
0.00
|
| Amortization Of Securities |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Change In Income Tax Payable |
|
0.21
+198.12%
|
-0.21
-155.04%
|
0.39
|
0.00
|
| Change In Tax Payable |
|
0.21
+198.12%
|
-0.21
-155.04%
|
0.39
|
0.00
|
| Common Stock Issuance |
|
—
|
0.00
-100.00%
|
0.22
-99.10%
|
24.51
|
| Issuance Of Capital Stock |
|
—
|
0.00
-100.00%
|
0.22
-99.10%
|
24.51
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-13 View
- 8-K2026-05-13 View
- 42026-05-06 View
- 8-K2026-03-26 View
- 10-K2026-03-26 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-05 View
- 42026-02-04 View
- 8-K2026-01-30 View
- 8-K2025-12-19 View
- 8-K2025-11-13 View
- 10-Q2025-11-13 View
- 42025-11-12 View
- 42025-09-03 View
- 42025-09-03 View
- 10-Q2025-08-12 View
- 8-K2025-08-12 View
- 8-K2025-06-18 View
- 42025-06-16 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|